Braidwell LP boosted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 396,781 shares of the biotechnology company's stock after buying an additional 73,272 shares during the quarter. Repligen makes up about 1.7% of Braidwell LP's investment portfolio, making the stock its 23rd biggest holding. Braidwell LP owned approximately 0.71% of Repligen worth $59,049,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Swedbank AB bought a new stake in shares of Repligen in the 1st quarter valued at approximately $5,518,000. First Turn Management LLC bought a new stake in Repligen during the third quarter valued at $13,202,000. Banque Pictet & Cie SA raised its holdings in shares of Repligen by 74.6% during the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock worth $4,351,000 after purchasing an additional 14,746 shares during the period. Geneva Capital Management LLC lifted its position in shares of Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock worth $20,638,000 after buying an additional 10,908 shares during the last quarter. Finally, Diversified Trust Co boosted its holdings in shares of Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after buying an additional 106 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Price Performance
Shares of RGEN stock traded up $0.55 during midday trading on Friday, reaching $150.54. 225,812 shares of the company were exchanged, compared to its average volume of 664,788. The company's 50 day moving average price is $140.98 and its two-hundred day moving average price is $142.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market cap of $8.43 billion, a P/E ratio of -406.86, a PEG ratio of 4.52 and a beta of 0.96. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 earnings per share. On average, sell-side analysts expect that Repligen Co. will post 1.52 earnings per share for the current year.
Insider Buying and Selling at Repligen
In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
RGEN has been the topic of a number of recent research reports. Benchmark reissued a "hold" rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating on the stock. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $190.25.
Read Our Latest Research Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
